Article Text

Download PDFPDF
Articles of interest in other scholarly journals
  1. Jason W Boland1,2
  1. 1Senior Clinical Lecturer and Honorary Consultant in Palliative Medicine, Hull York Medical School, University of Hull, UK
  2. 2Care Plus Group and St Andrew's Hospice, NE Lincolnshire, UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Randomised double-blind trial of pregabalin versus placebo in conjunction with palliative radiotherapy for cancer-induced bone pain

▸ Fallon M, Hoskin PJ, Colvin LA, et al. J Clin Oncol 2015. Published Online First.

In a multicenter, double-blind randomised trial in adults with moderate to severely painful radiologically-proven bone metastases due to receive radiotherapy, pregabalin (titrated over 4 weeks) was compared to placebo. From nearly 2000 patients screened, 233 were randomly assigned (the target was 260): 117 to placebo and 116 to pregabalin; all were included in the analysis. Patients had a variety of cancers, with prostate, breast and lung being the most common. In the pregabalin arm, 45 patients (39%) had a reduction of ≥2 points in worst pain by week 4 (the primary end point), compared with 47 (40%) in the placebo arm. The secondary end points of average pain, pain interference, or quality of life were also the same between arms. There were significant improvements in mood and a decrease in breakthrough pain episodes with pregabalin. There were no differences …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.